These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 22143533

  • 1. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
    Gonzalez-Serna A, McGovern RA, Harrigan PR, Vidal F, Poon AF, Ferrando-Martinez S, Abad MA, Genebat M, Leal M, Ruiz-Mateos E.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1202-7. PubMed ID: 22143533
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
    Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B, ANRS AC11 Resistance Study Group.
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
    [Abstract] [Full Text] [Related]

  • 3. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
    Cascajero A, Rastrojo A, Díez-Fuertes F, Hernández-Novoa B, Aguado B, Moreno S, Alcami J, Pérez-Olmeda M.
    J Virol; 2018 Jun 01; 92(11):. PubMed ID: 29563289
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of maraviroc on HIV disease progression-related biomarkers.
    Romero-Sánchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, García-García M, Alvarez-Ríos AI, Ferrando-Martinez S, Ruiz-Mateos E, Leal M.
    Antimicrob Agents Chemother; 2012 Nov 01; 56(11):5858-64. PubMed ID: 22948867
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
    Rossetti B, Bianco C, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A.
    AIDS Res Hum Retroviruses; 2014 Jan 01; 30(1):17-24. PubMed ID: 23971941
    [Abstract] [Full Text] [Related]

  • 8. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
    Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.
    J Infect Dis; 2011 Jan 15; 203(2):237-45. PubMed ID: 21288824
    [Abstract] [Full Text] [Related]

  • 9. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
    Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.
    Antimicrob Agents Chemother; 2013 Dec 15; 57(12):6122-30. PubMed ID: 24080655
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
    McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.
    J Acquir Immune Defic Syndr; 2012 Nov 01; 61(3):279-86. PubMed ID: 23095934
    [Abstract] [Full Text] [Related]

  • 12. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
    Reuter S, Braken P, Jensen B, Sierra-Aragon S, Oette M, Balduin M, Kaiser R, Häussinger D.
    Eur J Med Res; 2010 Jun 28; 15(6):231-7. PubMed ID: 20696631
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
    McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.
    AIDS; 2010 Oct 23; 24(16):2517-25. PubMed ID: 20736814
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Methods for determination of HIV tropism and their clinical use].
    Gutiérrez F, Rodríguez JC, García F, Poveda E.
    Enferm Infecc Microbiol Clin; 2011 Dec 23; 29 Suppl 5():45-50. PubMed ID: 22305669
    [Abstract] [Full Text] [Related]

  • 19. Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.
    Sierra S, Dybowski JN, Pironti A, Heider D, Güney L, Thielen A, Reuter S, Esser S, Fätkenheuer G, Lengauer T, Hoffmann D, Pfister H, Jensen B, Kaiser R.
    PLoS One; 2015 Dec 23; 10(5):e0125502. PubMed ID: 25970632
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.